FDA Official's Controversial Hiring Sparks Debate Over Antidepressant Warnings During Pregnancy
A top FDA official is attempting to hire a long-time friend who advocates for adding unproven pregnancy risk warnings to antidepressant labels. This move has drawn criticism from medical experts and internal FDA sources, who cite a conflict of interest and a lack of robust scientific data to support such warnings. The debate highlights the critical balance between patient safety and access to essential mental health treatments for pregnant women.
Read